Report to Board of Directors For Information
Author : phoebe-click | Published Date : 2025-05-29
Description: Report to Board of Directors For Information Finance Report September 2021 Month 6 FY22 1 Executive Summary Income Statement Clinical Income NonClinical Income Agency Cost Improvement Plan Statement of Position Cashflow Working Capital
Presentation Embed Code
Download Presentation
Download
Presentation The PPT/PDF document
"Report to Board of Directors For Information" is the property of its rightful owner.
Permission is granted to download and print the materials on this website for personal, non-commercial use only,
and to display it on your personal computer provided you do not modify the materials and that you retain all
copyright notices contained in the materials. By downloading content from our website, you accept the terms of
this agreement.
Transcript:Report to Board of Directors For Information:
Report to Board of Directors For Information Finance Report September 2021 (Month 6), FY22 1 Executive Summary Income Statement Clinical Income Non-Clinical Income Agency Cost Improvement Plan Statement of Position Cash-flow Working Capital Indicators Capital Investment Programme Reconciliation to NHSI Template Contents A risk assessment has been undertaken around the legal issues that this paper presents and there are no issues that need to be referred to the Trust Solicitors. Circulated outside of a Board meeting Confidential Executive Summary The year-to-date I&E position at month 6 is a £3.1m surplus, £0.1m favourable to plan. EBITDA is a £8.2m surplus, £0.2m adverse to plan. The FY22 plan is for a breakeven position with a £3.0m surplus in the first half of the year and a £3.0m deficit in the second half of the year. The favourable position is driven by slippage on investments and by £2.7m underspend against the allocation for Covid-19 costs. This is despite overspend in services in particular the Oxon & BSW MH directorate (£3.7m) compounded by high agency usage. Finance are working with the directorate on the causes of this overspend and an action plan to address it. CIP savings YTD are £0.8m, £0.6m adverse to plan due to a delay in CIP engagement as a result of Covid-19. Capital spend is £2.2m, £3.9m adverse to plan. The closing cash position at the end of September was £52.7m, £2.0m favourable to plan. Recommendation: The Board of Directors are asked to note the Finance Report against plan and seek any further assurances as required. 2 Confidential 1. Income Statement . 3 The year-to-date I&E position at month 6 is a £3.1m surplus, £0.1m favourable to plan (£1.5m surplus, £1.0m adverse to plan at month 5). EBITDA is a £8.2m surplus, £0.2m adverse to plan. The FY22 plan is for a breakeven position with a £3.0m surplus in the first half of the year and a £3.0m deficit in the second half of the year. The favourable position is driven by slippage on investments and by £2.7m underspend against the allocation for Covid-19 costs. This is despite overspend in services in particular the Oxon & BSW MH directorate (£3.7m) compounded by high agency usage. Finance are working with the directorate on the causes of this overspend and an action plan to address it. Budgets have been set for mental health new investment funding in line with plans although this
